GAIN THERAPEUTICS, INC Payments of Stock Issuance Costs
GAIN THERAPEUTICS, INC (GANX) reported Payments of Stock Issuance Costs of $395.48 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-26
- GAIN THERAPEUTICS, INC payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- GAIN THERAPEUTICS, INC payments of stock issuance costs for the quarter ending 2024-12-31 was $0.00.
- GAIN THERAPEUTICS, INC payments of stock issuance costs for the quarter ending 2024-09-30 was $0.00.
- GAIN THERAPEUTICS, INC payments of stock issuance costs for the quarter ending 2024-06-30 was $0.00.
- GAIN THERAPEUTICS, INC payments of stock issuance costs for fiscal 2025 was $395.48K, a 40.81% increase from fiscal 2024.
- GAIN THERAPEUTICS, INC payments of stock issuance costs for fiscal 2024 was $280.87K.
- GAIN THERAPEUTICS, INC payments of stock issuance costs for fiscal 2021 was $853.49K, a 81.31% increase from fiscal 2020.
- GAIN THERAPEUTICS, INC payments of stock issuance costs for fiscal 2020 was $470.75K.
| Period end | Payments of Stock Issuance Costs 2 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $395.48K 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $395.48K 10-Q · filed 2025-11-12 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $280.87K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $280.87K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $280.87K 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $280.87K 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | $900.00K 10-K · filed 2024-03-26 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $213.79K derived: sum of 3 quarters · filed 2023-03-23 | $853.49K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $213.79K derived: sum of 2 quarters · filed 2022-11-10 | $853.49K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $213.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $853.49K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $639.69K 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $470.75K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |